Application of FDG-PET and Molecular Gene Profiling for Risk Stratification of Diffuse Large B-Cell Non-Hodgkin’s Lymphoma in Different Ethnic Populations

Closed for proposals

Project Type

Coordinated Research Project

Project Code




Approved Date

3 July 2006



Start Date

15 September 2006

Expected End Date

31 March 2012

Completed Date

31 December 2012


Diffuse Large B-Cell non-Hodgkin’s Lymphoma (DLBCL) is an aggressive form of non-Hodgkin’s Lymphoma (NHL). During the past 30 years the treatment of DLBCL has evolved to a point where the disease is curable in many patients. The introduction of Positron Emission Tomography (PET) has made a critical contribution to the accurate definition of clinical stage at presentation and the accurate assessment of disease clearance at the end of treatment. More recently early interim PET has been shown to be a good indicator of potential for cure. Gene expression profiling (GEP) of DLBCL has been demonstrated to identify disease subsets with both biological and clinical significance and to provide an independent predictor of response to treatment.


To establish the application of novel nuclear based and related in vitro molecular and biotechnological methods for effective investigation and management of infectious, neoplastic, metabolic, genetic and degenerative diseases in Member States.

Specific objectives

To develop prognostic algorithms to improve the treatment and outcome of patients with aggressive non-Hodgkin’s Lymphoma in developing countries.

Stay in touch